The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2

Abstract

Mutations in the X-linked gene MECP2 are associated with a severe neurodevelopmental disorder, Rett syndrome (RTT), primarily in girls. It had been suspected that mutations in Methyl-CpG-binding protein 2 (MECP2) led to embryonic lethality in males, however such males have been reported. To enhance understanding of the phenotypic spectrum present in these individuals, we identified 30 males with MECP2 mutations in the RTT Natural History Study databases. A wide phenotypic spectrum was observed, ranging from severe neonatal encephalopathy to cognitive impairment. Two males with a somatic mutation in MECP2 had classic RTT. Of the remaining 28 subjects, 16 had RTT-causing MECP2 mutations, 9 with mutations that are not seen in females with RTT but are likely pathogenic, and 3 with uncertain variants. Two subjects with RTT-causing mutations were previously diagnosed as having atypical RTT; however, careful review of the clinical history determined that an additional 12/28 subjects met criteria for atypical RTT, but with more severe clinical presentation and course, and less distinctive RTT features, than females with RTT, leading to the designation of a new diagnostic entity, male RTT encephalopathy. Increased awareness of the clinical spectrum and widespread comprehensive genomic testing in boys with neurodevelopmental problems will lead to improved identification.

Keywords: MECP2; Rett syndrome; encephalopathy; genetics; male; neurodevelopmental disorders.

Figure 1:

Distribution variation of CSS based on MECP2 mutation type. Light blue circles=people with somatic mutations in MECP2. Orange triangles=people with early RTT-causing mutations in MECP2. Black diamonds= people with late RTT-causing mutations in MECP2. Yellow circles=people with pathogenic mutations in MECP2 that do not cause RTT in females. Dark blue circles=people with benign variants in MECP2